RenovoRx (RNXT) Change in Receivables (2025 - 2026)
RenovoRx (RNXT) posted Change in Receivables of $141000.0 for Q1 2026, up 570.0% sequentially from -$30000.0 in Q4 2025, and down 29.15% YoY from $199000.0 in Q1 2025.
RenovoRx (RNXT) Change in Receivables (2025 - 2026) Analysis & Trends
RenovoRx has reported Change in Receivables for 2 years, with the latest figure at $141000.0 in Q1 2026.
- Quarterly Change in Receivables fell 29.15% year-over-year to $141000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38000.0 (changed N/A YoY) and the FY2025 annual result came in at $96000.0, changed N/A from the prior year.
- Change in Receivables improved to $141000.0 in Q1 2026 per RNXT's latest filing, from -$30000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $199000.0 in Q1 2025 and troughed at -$194000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 141,000.00 |
| Mar 31, 2026 | 141,000.00 |
| Dec 31, 2025 | -30,000.00 |
| Dec 31, 2025 | -30,000.00 |
| Sep 30, 2025 | -194,000.00 |
| Sep 30, 2025 | -194,000.00 |
| Jun 30, 2025 | 121,000.00 |
| Jun 30, 2025 | 121,000.00 |
| Mar 31, 2025 | 199,000.00 |
| Mar 31, 2025 | 199,000.00 |